Bristol Myers Squibb

BMY Health Care Market cap $131B as of Sep 14, 2026 16:00 ET S&P 500

Q2 FY26 Apr 1 – Jun 30, 2026 reported Jul 30, 2026

Revenue$12.97B +6% year over year

Gross profit$9.25B 71% margin

Operating profit−$0.83B −6% margin

Net profit$3.32B 26% margin

Net profit is larger than what operations earned, because the statement adds $4.92B below it, under Other income, net.

The numbers behind the diagram

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 30, 2026).
Item	Value	Share of revenue	Year over year
Revenue	12.97	100%	+6%
Growth portfolio	7.56	58%
Eliquis	4.48	35%
Revlimid	0.43	3%
Pomalyst/Imnovid	0.20	2%
Other legacy products	0.17	1%
Sprycel	0.09	1%
Abraxane	0.06	0%
Cost of revenue	−3.73	29%
Gross profit	9.25	71% margin	−1pp
R&D	−2.96	23%	+2pp
SG&A	−1.83	14%	+0pp
Other	−5.29	41%	+0pp
Operating profit	−0.83	−6% margin
Other income, net	4.92
Tax	−0.77
Net profit	3.32	26% margin	+15pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	11.5	100%	+3%
Eliquis	4.1	36%
Opdivo	2.1	19%
Other revenue	2.1	18%
Orencia	0.8	7%
Yervoy	0.7	6%
Other growth products	0.6	5%
Reblozyl	0.6	5%
Pomalyst/Imnovid	0.5	4%
Cost of revenue	−3.4	30%
Gross profit	8.1	70% margin	−3pp
R&D	−2.6	23%	+3pp
SG&A	−1.6	14%	+0pp
Other	−4.3	38%
Operating profit	−0.5	−5% margin	+0pp
Other income, net	3.8
Tax	−0.6
Net profit	2.7	23% margin	+1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	12.22	100%	+3%
Growth portfolio	6.86	56%	+18%
Eliquis	3.75	31%	+25%
Pomalyst/Imnovid	0.68	5%	−25%
Revlimid	0.58	5%	−59%
Other legacy products	0.18	1%	−21%
Sprycel	0.12	1%	−59%
Abraxane	0.07	1%	−71%
Cost of revenue	−3.44	28%
Gross profit	8.79	72% margin	−3pp
R&D	−2.53	21%	+1pp
SG&A	−1.79	14%	−2pp
Other	−5.50	45%	+0pp
Operating profit	−1.03	−8% margin	+0pp
Other income, net	4.15
Tax	−0.92
Net profit	2.20	18% margin	+8pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	12.27	100%	+1%
Growth portfolio	6.60	53%
Eliquis	3.68	30%
Revlimid	0.84	7%
Pomalyst/Imnovid	0.71	6%
Other legacy products	0.22	2%
Sprycel	0.12	1%
Abraxane	0.11	1%
Cost of revenue	−3.37	27%
Gross profit	8.90	73% margin	−1pp
R&D	−2.58	21%	−3pp
SG&A	−1.71	14%	−2pp
Other	−5.07	41%	+0pp
Operating profit	−0.46	−4% margin	+0pp
Other income, net	2.23
Tax	−0.46
Net profit	1.31	11% margin	−3pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY25 (period ends Mar 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	11.20	100%	−6%
Eliquis	3.57	32%
Opdivo	2.27	20%
Other revenue	1.96	17%
Revlimid	0.94	8%
Orencia	0.77	7%
Pomalyst/Imnovid	0.66	6%
Yervoy	0.62	6%
Reblozyl	0.48	4%
Other and unallocated	−0.05	0%
Cost of revenue	−3.03	27%
Gross profit	8.17	73% margin	−2pp
R&D	−2.26	20%	−3pp
SG&A	−1.58	14%	−6pp
Other	−4.84	43%	+0pp
Operating profit	−0.51	−5% margin	+0pp
Other income, net	3.48
Tax	−0.51
Net profit	2.46	22% margin	+122pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

Financial health

The balance sheet, the quarter's capital flow, the debt schedule and the capital structure of the quarter shown above.

Every set of results we hold, newest first. Open one on its own page.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q2 FY26 Apr 1 – Jun 30, 2026 reported Jul 30, 2026 Operating margin −6% Net profit $3.3B	Apr 1 – Jun 30, 2026	Jul 30, 2026	$13.0B	+6%	−6%	$3.3B	26%
Q1 FY26 Jan 1 – Mar 31, 2026 reported Apr 30, 2026 Operating margin −5% Net profit $2.7B	Jan 1 – Mar 31, 2026	Apr 30, 2026	$11.5B	+3%	−5%	$2.7B	23%
Q3 FY25 Jul 1 – Sep 30, 2025 reported Oct 30, 2025 Operating margin −8% Net profit $2.2B	Jul 1 – Sep 30, 2025	Oct 30, 2025	$12.2B	+3%	−8%	$2.2B	18%
Q2 FY25 Apr 1 – Jun 30, 2025 reported Jul 31, 2025 Operating margin −4% Net profit $1.3B	Apr 1 – Jun 30, 2025	Jul 31, 2025	$12.3B	+1%	−4%	$1.3B	11%
Q1 FY25 Jan 1 – Mar 31, 2025 reported Apr 24, 2025 Operating margin −5% Net profit $2.5B	Jan 1 – Mar 31, 2025	Apr 24, 2025	$11.2B	−6%	−5%	$2.5B	22%